Pro-inflammatory cytokines including tumour necrosis factor (TNF) mediate the pathogenesis of hepatitis C virus (HCV) infection. The distribution of TNF gene polymorphisms was examined among cirrhotic and non-cirrhotic patients infected with HCV. Thirty Caucasians with cirrhosis due to chronic HCV infection and 114 HCV-infected patients histopathologically free of cirrhosis were genotyped for genetic variants in TNF, lymphotoxin ␣ and TNF-receptor type I using PCR-based techniques. Variability in the progression of HCV-related cirrhosis was assessed in a multivariate model including genetic and non-genetic factors such as gender, estimated duration of infection, alcohol consumption, and viral genotype. Viral genotype and non-genetic host features were not independently related to the occurrence or rate of development of cirrhosis in the patient population. In contrast, the TNF promoter variants TNF2 (−238A) and TNF3 (−308A) conferred a 3.2-fold and 5.1-fold risk of cirrhosis respectively (P = 0.03 for both). Reciprocal effects were observed with several TNF alleles and haplotypes defined by the −238G/A and −308G/A dimorphic sequences. Polymorphisms in the TNF␣ promoter appear to be associated with variability in the histological severity of chronic hepatitis C infection. Genes and Immunity (2000) 1, 386-390.
Introduction
Chronic infection with hepatitis C virus (HCV) is characterized by a broad spectrum of clinical manifestations that can eventually culminate in decompensated cirrhosis and hepatocellular carcinoma. Histopathologically, varying degrees of inflammation, fibrosis, and cirrhosis may be detected. An estimated 20-30% of infected individuals will develop cirrhosis while others largely remain asymptomatic. [1] [2] [3] [4] [5] [6] The contrasting outcomes of HCV infection have been attributed to viral genotypes and external modulators including alcohol consumption, [7] [8] [9] but immunoregulatory host factors are also likely to be involved.
Cytokines in the tumor necrosis factor (TNF) system serve as key immunologic mediators of the inflammatory response and apoptosis. 10, 11 In addition, TNF can potentially affect liver fibrogenesis by stimulating hepatic stellate cells, which are the principal cells involved with this process (reviewed by Friedman) . 12 Products encoded by TNF␣ and lymphotoxin alpha (LT␣, formerly known as TNF␤) typically function as homotrimers or heterotrimers that interact with two forms of TNF receptor (TNFR1 and TNFR2). A wide range of TNF␣ production has been observed and can be attributed to polymorphisms in the TNF␣ promoter and their corresponding extended HLA haplotypes. 13 In particular, two common biallelic variants at the −238 (G or A) and −308 (G or A) positions of the TNF␣ promoter have been the first to receive attention, 14, 15 with the −308A (TNF2) being associated with enhanced promoter activity by in vitro assay. 16, 17 In addition, LT␣ and TNFR1 also carry polymorphisms, which include a variable number of dinucleotide (CT/GA) repeat sequences (TNFc microsatellite) in the first intron of LT␣, an amino acid substitution in exon-1 (amino acid 26 Thr/Asn) in LT␣, 18 and an A-to-C nucleotide substitution in the TNFR1 promoter. The functional relevance of these variations remains undefined.
Elevated production of TNF␣ is a common feature in multiple autoimmune and infectious diseases (reviewed by Zhang et al). 19 Accordingly, several studies have revealed relationships between TNF␣ promoter variants and clinical outcomes in cerebral malaria, primary sclerosing cholangitis, and primary biliary cirrhosis. [20] [21] [22] The TNFc microsatellite c2 allele has further been associated with slower disease progression in HIV infection. 23 However, in the absence of plausible functional mechanisms these relationships may simply imply the strong linkage between TNF variants and others in neighboring regions. 17, 24 The TNF pathway has been shown more recently to be involved in the immune response to viral hepatitis, [25] [26] [27] which prompted us to examine the distribution of common polymorphisms in the TNF system among HCVinfected patients.
Results

Frequency of TNF polymorphisms
Allelic and phenotypic variants in the TNF␣ promoter, LT␣, and TNFc microsatellite loci were common and their frequencies were comparable with those seen in other studies of Caucasians (Table 1) . Observed genotypic frequencies approximated those expected based on allele frequency calculations, and thus conformed to Hardy-Weinberg equilibrium.
On the other hand, TNF receptor promoter sequence variation was infrequent: among the 24 cases and 51 controls typed for the TNFR1 polymorphisms, only two (2.7%) individuals carried the variant C allele, both of which were control subjects (3.9%). The rarity of sequence variation in TNFR1 did not allow any further meaningful analyses, and genotyping at this locus was not applied to the remaining patients.
CD4 STR allele frequencies
Consistent with population-specific data reported before, 28 the most prevalent CD4-STR alleles observed in our population were 85-bp (43.1%), 90-bp (26.0%), 100-bp (0.3%), 110-bp (27.1%), 115-bp (2.1%), and 120-bp (1.4%) in size. Genotype frequencies also fit expectations by Hardy-Weinberg equilibrium, and their distributions were consistent with previous data for general Caucasian populations.
Univariate and multivariate comparisons between HCV patient groups
The two patient groups with and without cirrhosis were comparable in terms of ALT levels, HCV viral load, viral genotypes, gender, estimated duration of HCV infection, and alcohol use (data not shown), and the same was true for the LT␣ 26 Thr/Asn variants. However, different distributions were noted in the TNF alleles, phenotypes, genotypes, and haplotypes among the patient groups (Tables 2 and 3 ). Specifically, the −238A (TNF3) and −308A (TNF2) alleles and the TNF3 and TNF2 phenotypes were more common among patients who suffered from cirrhosis than patients without cirrhosis, although only the TNF2 phenotype was statistically significant by univariate analysis. These relationships were extended to the c1(TNFc)-TNF2 (OR = 2.3; 95% CI: 1.0-5.6; P = 0.0477) and c2(TNFc)-TNF3 (OR = 3.8; 95% CI: 1.2-12.3; P = 0.0198) haplotypes as well. We further studied the TNF promoter variants through the use of multivariate logistic regression. Model I (Table  4 ) controls for the relative contribution of both promoter variants and suggests that the −238A and −308A variants each confer a risk for cirrhosis (Table 4) . When adjustments for non-genetic factors were included, the −238A and −308A frequencies remained different between the patient categories (Table 4 ; model II). Interaction between the −238A and −308A sites was not detected (data not shown).
Discussion
The present study provides support for the role of immunogenetic host factors as a determinant of the outcome of chronic HCV infection. Among the genetic and nongenetic factors defined for the HCV-infected patient groups studied here, the TNF␣ promoter variants TNF2, TNF3, and their related haplotypes were clearly associated with cirrhosis. The TNF␣ promoter variants are dimorphic sites. Accordingly, reciprocal associations (protection) were also observed for the TNF1 allele. In addition, genetic data from TNF loci as well as the CD4 STR locus indicated that the patient population in our study is comparable with the general Caucasian population. Therefore, the TNF relationships to HCV-related cirrhosis are likely to extend to other studies involving Caucasian subjects. Multivariate logistic regression adjusting for the simultaneous contributions of both variants indicated that the −238A and the −308A markers each conferred increased risk of cirrhosis, with the TNF2 and the TNF3 variants showing a 2.8-fold and 3.6-fold higher risk, respectively (Table 4 ; model I). The TNF promoter variant −238A has previously been associated with failure to clear virus in both hepatitis B and hepatitis C infections, possibly due to altered TNF expression caused by a nucleotide substitution in a putative regulatory region of the promoter. 26, 27 The −308A promoter variant has been associated with enhanced transcription of TNF, 16 but other investigations have failed to reproduce this finding. 24 Since TNF is located in the central MHC region where other polymorphic loci are abundant, it is possible that linkage disequilibria among genetic markers in the TNF and major histocompatibility complex (MHC) genes can offer the ultimate explanation for the disease associations we frequently encounter. The strong haplotypic associations with c2(TNFc)-TNF3 (Table 3 ) and cirrhosis might well reflect one of these phenomena. As a result, it is still impossible at this stage to pinpoint the biological mechanisms for the population effect we observed. Further genotyping of the HLA region and of nearby loci should help define the extended haplotypes and further refine our understanding of these often complex relationships. Our data also indicated that differences in disease outcome among patients with established chronic HCV infections (average duration of infection 23 years) could have more to do with immunogenetic factors than with patient gender, duration of infection, alcohol consumption, and HCV viral genotypes. Alcohol use alone has been shown to contribute to the progression of fibrosis in HCV infection. [7] [8] [9] Our lack of a detectable independent deleterious effect may deserve further investigation based on an increased sample size, especially as controlling the effects of factors such as viral genotypes, alcohol consumption, patient gender and duration of infection through multivariate modeling produced genetic associations with slightly increased strength (Table 4 ; model II). Patient gender, viral genotypes and the duration of infection are not significant independent contributors to cirrhotic outcome compared to the host genetic factors examined. Furthermore, our data highlight the importance of multivariate analyses in complex systems such as multiple linked genetic polymorphisms.
Materials and methods
Study subjects, estimations of disease duration, and clinical data
Caucasian patients with compensated liver disease who were enrolled in a trial of combination therapy with interferon-␣ 2b + ribavirin for chronic HCV infection at two large tertiary care centers in the southeastern United States were studied. Patients with cirrhosis or probable cirrhosis were designated cases; those histopathologically free of were selected as controls. All were 18-70 years old and free of other forms of chronic liver disease and infection with the human immunodeficiency virus (HIV). Duration of hepatitis C infection was estimated using a detailed, interviewer-assisted questionnaire assessing risk factors for hepatitis C. 29 When multiple risk factors were present, the earliest exposure was designated as the point of acquisition. 29 Patients were classified into one of four groups based on self-reported levels of alcohol consumption prior to HCV diagnosis: no alcohol use; 1-5 drinks/year; у2-3 drinks/month to 3-4 drinks/week; at least 1 drink daily or nearly every day. HCV genotyping and plasma viral load measurements (copies/mL) were performed by the National Genetics Institute (Los Angeles, CA, USA) and analyzed by tertiles: Ͻ1 million; у1 million but Ͻ 4million; у4 million. Pre-treatment values for alanine amino transferase (ALT) were measured in the UAB clinical laboratories and were analyzed by quartiles: р63; Ͼ63 and р97; Ͼ97 and р144; Ͼ144.
DNA extraction and PCR-based genotyping of TNF␣, LT␣, TNFc, and TNFR1 allelic variants Genomic DNA was isolated from whole buffy coats of participants using standard inorganic salt-out procedures 30, 31 High resolution polymerase chain reaction with sequence-specific primers (PCR-SSP) was used to define polymorphisms in the TNF␣ promoter at positions −238 and −308, and at LT␣ position 26. 18 Reference samples whose TNF␣ and LT␣ alleles had been established by DNA sequencing and restriction enzyme digestion were used to validate the SSP-based genotyping strategy. The A-to-C nucleotide substitution in the TNFR1 promoter results in the loss of a Bgl II restriction site (GenBank sequence AF047488), and an expedited genotyping technique based on PCR-SSP was also developed (J Tang, unpublished).
TNFc microsatellite alleles were amplified by PCR and separated on denaturing gels as reported previously, 32 except that the 5Ј primer was labelled with Cy5 to facilitate detection of PCR amplicons on the ALFexpress automated DNA sequencer (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The 93-and 95-bp amplicons corresponded to the c1 and c2 alleles of the TNFc microsatellite, respectively.
Genotyping of CD4 short tandem repeat (STR)
Variable numbers of a pentanucleotide repeat sequence located in a potential silencer element of the CD4 gene (CD4-STR) on chromosome 12 provide a reliable microsatellite marker with specificity for the major modern human populations. 28, 33 Alleles at this informative locus were also identified using existing PCR-based techniques. 34 
Statistical analyses
Univariate associations between individual genetic factors and cirrhosis were examined using the 2 test. An odds ratio (OR) estimated the strength of association between a genetic marker and the presence of cirrhosis. Univariate and multivariate logistic regression was used to assess associations between cirrhosis and categorical explanatory variables, such as gender, presence of genetic markers, ALT level, viral load, viral genotype, estimated duration of HCV infection and alcohol use. In the first multivariate model, the relative contributions of TNF promoter variants were assessed. In the second multivariate model, the relative contributions of these same factors were assessed with adjustment for other factors previously suggested to play a role in the development of fibrosis. All statistical analyses were conducted using SAS® software (Cary, NC, USA). Due to the exploratory nature of this study, we elected not to apply the Bonferroni adjustment.
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